T. Rowe Price Investment Management, Inc. filed a Schedule 13G with the SEC on November 6, 2026, disclosing beneficial ownership of 7,905,757 shares of Xenon Pharmaceuticals Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: T. Rowe Price Investment Management, Inc. reported beneficial ownership of 7,905,757 shares of Xenon Pharmaceuticals Inc. common stock.
  • Percent of class: The reported stake represents 8.2% of the outstanding class of common stock, according to the filing.
  • Sole voting power: The filing discloses sole voting power over 7,558,551 shares, with 0 shares subject to shared voting power.
  • Sole dispositive power: T. Rowe Price Investment Management holds sole dispositive power over all 7,905,757 shares, with no shared dispositive power reported.
  • Triggering event date: The date of event requiring the filing is listed as September 30, 2026.
  • Filer type: The reporting person is classified as an investment adviser (type "IA"), organized under the laws of Maryland.

T. Rowe Price Discloses Passive 8.2% Position in Xenon Pharmaceuticals Common Stock

According to the Schedule 13G filed November 6, 2026, T. Rowe Price Investment Management, Inc., headquartered at 1307 Point Street, Baltimore, MD 21231, reported aggregate beneficial ownership of 7,905,757 shares of common stock (CUSIP 98420N105) of Xenon Pharmaceuticals Inc., whose principal executive offices are listed at 200 - 3650 Gilmore Way, Burnaby, A1, V5G 4M1. The filing identifies the reporting person as an investment adviser and states that the event triggering the filing occurred on September 30, 2026.

The filing reports that T. Rowe Price Investment Management holds sole voting power over 7,558,551 shares and sole dispositive power over the full 7,905,757 shares. Shared voting power and shared dispositive power are each reported as 0. The 8.2% figure represents the percent of class as disclosed in the filing. No subsidiary, group membership, or parent holding company relationship is identified as applicable.

The filing includes a certification, signed by Ellen York, Vice President, stating that "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing further notes that T. Rowe Price Investment Management "expressly denied" that the filing constitutes an admission of beneficial ownership as defined under applicable rules.

What Was Disclosed

T. Rowe Price Investment Management, Inc. filed a Schedule 13G disclosing beneficial ownership of 7,905,757 shares, or 8.2%, of Xenon Pharmaceuticals Inc. common stock as of September 30, 2026, with sole voting power over 7,558,551 shares and full sole dispositive power.